Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: An exploratory analysis of TEXT and SOFT

Annals of Oncology

Volumn 28, Issue 9, 2017, Pages 2225-2232

  Regan, M M ^a,b   Walley, B A ^c   Francis, P A ^d,e   Fleming, G F ^f   Lang I ^g   Gomez H L ^h   Colleoni, M ⁱ   Tondini, C ^j   Pinotti, G ^k   Salim, M ^l   Spazzapan, S ^m   Parmar, V ⁿ   Ruhstaller, T ^o,p   Abdi, E A ^q   Gelber, R D ^a,r   Coates, A S ^s   Goldhirsch, A ⁱ   Pagani, Olivia ^t,u  

^a HARVARD MEDICAL SCHOOL   (United States)

^b International Breast Cancer Study Group Statistical Center   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Breast Cancer Action Group   (Australia)

^f UNIVERSITY OF CHICAGO   (United States)

^g NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^h INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

ⁱ EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^k OSPEDALE DI CIRCOLO   (Italy)

^l Allan Blair Cancer Center   (Canada)

^m CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

ⁿ TATA MEMORIAL HOSPITAL   (India)

^o SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^p International Breast Cancer Study Group   (Switzerland)

^q GRIFFITH UNIVERSITY   (Australia)

^r FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^s UNIVERSITY OF SYDNEY   (Australia)

^t ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^u The International Breast Cancer Study Group   (Switzerland)

more..

Author keywords

Adjuvant therapy; GnRH agonist; Hormone receptor positive; Ovarian function suppression; Premenopausal; Triptorelin

Indexed keywords

EXEMESTANE; TAMOXIFEN; TRIPTORELIN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; BREAST CANCER FREE INTERVAL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; INFORMED CONSENT; MAJOR CLINICAL STUDY; MIDDLE AGED; ONCOLOGICAL PARAMETERS; OVARIAN FUNCTION SUPPRESSION; OVARY FUNCTION; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BREAST TUMOR; CLINICAL TRIAL; DRUG EFFECT; OVARY; PATHOPHYSIOLOGY;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OVARY; PREMENOPAUSE;

EID: 85029878235     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx285     Document Type: Article

References (28)

1. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; 2: 104-107
2. LHRH-Agonists in Early Breast Cancer Overview Group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007; 369: 1711-1723
3. Fornier MN, Modi S, Panageas KS et al. Incidence of chemotherapyinduced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005; 104: 1575-1579
4. Goldhirsch A, Gelber RD, Yothers G et al. Adjuvant therapy for very young women with breast cancer: need for tailored treatments. J Natl Cancer Inst Monogr 2001; 44-51
5. Aebi S, Gelber S, Castiglione-Gertsch M et al. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? Lancet 2000; 355: 1869-1874
6. Emons G, Grundker C, Gunthert AR et al. GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 2003; 10: 291-299
7. Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapyinduced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 1989; 7: 710-717
8. Sutherland RL, Green MD, Hall RE et al. Tamoxifen induces accumulation of MCF 7 human mammary carcinoma cells in the G0/G1 phase of the cell cycle. Eur J Cancer Clin Oncol 1983; 19: 615-621
9. Pico C, Martin M, Jara C et al. Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Ann Oncol 2004; 15: 79-87
10. Bedognetti D, Sertoli MR, Pronzato P et al. Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. J Natl Cancer Inst 2011; 103: 1529-1539
11. Albain KS, Barlow WE, Ravdin PM et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrineresponsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 2055-2063
12. Del Mastro L, Dozin B, Aitini E et al. Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest-Mammella Intergruppo (GONO-MIG) Group. Ann Oncol 2008; 19: 299-307
13. Regan MM, Pagani O, Fleming GF et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials. Breast 2013; 22: 1094-1100
14. Francis PA, Regan MM, Fleming GF et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436-446
15. Pagani O, Regan MM, Walley BA et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-118
16. Burstein HJ, Lacchetti C, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol 2016; 34: 1689-1701
17. Coates AS, Winer EP, Goldhirsch A et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015
18. Paluch-Shimon S, Pagani O, Partridge AH et al. Second international consensus guidelines for breast cancer in young women (BCY2). Breast 2016; 26: 87-99
19. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Breast Cancer (Version 2.2016); https://www. nccn.org/professionals/physician_gls/pdf/breast.pdf (1 December 2016, date last accessed)
20. Austin PC. The use of propensity score methods with survival or timeto-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med 2014; 33: 1242-1258
21. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Statist Med 2015; 34: 3661-3679
22. Xie J, Liu C. Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data. Stat Med 2005; 24: 3089-3110
23. Pritchard KI. Combining endocrine agents with chemotherapy: which patients and what sequence? Cancer 2008; 112: 718-722
24. Sertoli MR, Scarsi PG, Rosso R. Rationale for combining chemotherapy and hormonal therapy in breast cancer. J Steroid Biochem 1985; 23: 1097-1103
25. Chia SK, WolffAC. With maturity comes confidence: EBCTCG tamoxifen update. Lancet 2011; 378: 747-749
26. Rimawi MF, Cecchini RS, Rastogi P et al. A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/-estrogen deprivation: NRG Oncology/NSABP B-52 (S03-06). San Antonio, TX: SABCS, 2016
27. Munhoz RR, Pereira AA, Sasse AD et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol 2016; 2: 65-73
28. Berliere M, Duhoux FP, Dalenc F et al. Tamoxifen and ovarian function. PLoS ONE 2013; 8: e66616